Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher A Eide

Showing results (51-60 of 83) with videos related to

Pageof 9
Sort By:
Oncotarget|June 7, 2018
Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samplesDavid K Edwards V, David Tyler Sweeney, Hibery Ho, et al.
Cancer Cell|August 30, 2024
Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapyChristopher A Eide, Diana Brewer, Tao Xie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2015
A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung CancerAlexander Drilon, Romel Somwar, Jacob P Wagner, et al.
Oncotarget|January 13, 2016
IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasmsPaula de Melo Campos, João A Machado-Neto, Christopher A Eide, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2017
CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracyLeyuan Ma, Jeffrey I Boucher, Janet Paulsen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2023
Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell DiseasesOlivia M Lucero, Ji-Ann Lee, Jenna Bowman, et al.
Cell Reports. Medicine|December 30, 2025
CDK4/6 inhibition overcomes venetoclax resistance mechanisms with enhanced combination activity in acute myeloid leukemiaMelissa L Stewart, Jessica Gibbs, Kevin Watanabe-Smith, et al.
Blood|October 9, 2014
BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoproteinAnupriya Agarwal, Ryan J Mackenzie, Arnaud Besson, et al.
Oncotarget|February 11, 2017
Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitorsPaavo O Pietarinen, Christopher A Eide, Pilar Ayuda-Durán, et al.
Oncogene|March 13, 2021
Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa BAlfonso E Bencomo-Alvarez, Andres J Rubio, Idaly M Olivas, et al.
Pageof 9

Showing results (51-60 of 83) with videos related to

Sort By:
Pageof 9
Oncotarget|June 7, 2018
Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samplesDavid K Edwards V, David Tyler Sweeney, Hibery Ho, et al.
Cancer Cell|August 30, 2024
Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapyChristopher A Eide, Diana Brewer, Tao Xie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2015
A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung CancerAlexander Drilon, Romel Somwar, Jacob P Wagner, et al.
Oncotarget|January 13, 2016
IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasmsPaula de Melo Campos, João A Machado-Neto, Christopher A Eide, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2017
CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracyLeyuan Ma, Jeffrey I Boucher, Janet Paulsen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2023
Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell DiseasesOlivia M Lucero, Ji-Ann Lee, Jenna Bowman, et al.
Cell Reports. Medicine|December 30, 2025
CDK4/6 inhibition overcomes venetoclax resistance mechanisms with enhanced combination activity in acute myeloid leukemiaMelissa L Stewart, Jessica Gibbs, Kevin Watanabe-Smith, et al.
Blood|October 9, 2014
BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoproteinAnupriya Agarwal, Ryan J Mackenzie, Arnaud Besson, et al.
Oncotarget|February 11, 2017
Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitorsPaavo O Pietarinen, Christopher A Eide, Pilar Ayuda-Durán, et al.
Oncogene|March 13, 2021
Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa BAlfonso E Bencomo-Alvarez, Andres J Rubio, Idaly M Olivas, et al.
Pageof 9